Not FDA-approved
Bones & muscles
CJC-1295
Evidence
Limited human data
Class
Growth hormone-releasing hormone analog
KEY TAKEAWAY
CJC-1295 is a synthetic analog of growth hormone-releasing hormone. A version bound to a drug affinity complex (DAC) lasts days rather than minutes. CJC-1295 is not FDA-approved. Development stopped after early clinical trials, and it has no approved use.
Written by the Veylo editorial team · Updated
November 2026
What it is
Growth hormone-releasing hormone analog
Main uses
Studied for growth hormone deficiency; sold online for body composition and anti-aging
Key fact
CJC-1295 is not FDA-approved. Development stopped after early clinical trials, and it has no approved use.
Route
Subcutaneous injection
Evidence strength
Limited human data
CJC-1295 is a synthetic analog of growth hormone-releasing hormone. A version bound to a drug affinity complex (DAC) lasts days rather than minutes.
It stimulates the pituitary gland to release growth hormone, which raises IGF-1.
CJC-1295 is not FDA-approved. Development stopped after early clinical trials, and it has no approved use.
Studied for growth hormone deficiency; sold online for body composition and anti-aging.
Water retention, flushing, headache and higher blood sugar are possible. Long-term safety is unknown, and products sold online are not quality-checked.
CJC-1295: see PubMed and ClinicalTrials.gov for published studies and registered trials. No FDA drug label exists for the uses described.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.